Bausch Health Companies Inc. Announces Second-Quarter 2021 Results

Go back to Bausch Health Companies Inc. Announces Second-Quarter 2021 Results

Bausch Health (BHC) Results 'Good', Solta Could Be Valued at $2.5B+ - Cowen

August 3, 2021 10:54 AM EDT

Cowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC) following results and news it plans to IPO the aesthetics Solta division.

The analyst commented, "BHC reported a good Q2 with revs and earnings essentially in-line; the... More

Bausch Health Co. Inc. (BHC) Reports In-Line Q2 Revenue, Updates Guidance

August 3, 2021 7:07 AM EDT

Bausch Health Co. Inc. (NYSE: BHC) reported Q2 EPS of ($1.66), may not compare to the analyst estimate of $0.95. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.12 billion.

GUIDANCE:

Bausch Health Co. Inc. sees FY2021 revenue of... More